1. Rogowski, W., Payne, K., Schnell-Inderst, P., Manca, A., Rochau, U., Jahn, B., Alagoz, O., Leidl, R., Siebert, U.: Concepts of ‘‘Personalization’’ in personalized medicine: implications for economic evaluation. PharmacoEconomics (2014). doi: 10.1007/s40273-014-0211-5
2. Hatz, M.H.M., Schremser, K., Rogowski, W.H.: Is individualized medicine more cost-effective? A systematic review. Pharmaco. Economics 32, 443–455 (2014)
3. Trusheim, M.R., Berndt, E.R., Douglas, F.L.: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 6, 28793 (2007)
4. Antoñanzas, F., Rodríguez-Ibeas, R., Hutter, M.F., Lorente, R., Juárez, C., Pinillos, M.: Genetic testing in the European Union: does economic evaluation matter? Eur J Health Econ 12(5), 651–662 (2012)
5. Antoñanzas, F., Juárez-Castelló, C.A., Rodríguez-Ibeas, R.: Some economics on personalized and predictive medicine. Eur J Health Econ (2014). doi: 10.1007/s10198-014-0647-8